Dry Eye – Landscape & Forecast – Disease Landscape & Forecast
Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a large prevalent pool in the G7 markets, the condition is underdiagnosed and few drugs are approved to treat it. As such, commercial opportunity abounds in this space. Indeed, despite the challenges in drug development for DED, the pipeline is robust, with a number of drugs in active late-phase development. With the expected launch of six new drugs for DED and the generic entry of AbbVie’s blockbuster Restasis in the United States, the DED therapy market is set to be dynamic and competitive over the next decade.
QUESTIONS ANSWERED
- How large is the prescription drug-treatable DED population in the G7 countries? How will drug-treatment rates change over the 2019-2029 forecast period?
- What is the current size of the DED market for key prescription therapies in the G7 countries? How will key events, including the generic availability of Restasis in the United States, influence the market over the next decade?
- What is the current state of DED treatment? Which are the most important prescription drug classes / drugs and why? What are interviewed experts’ insights on current treatment options?
- What are the biggest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs? What therapies of note are progressing in earlier phases?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 20 country-specific interviews with thought-leading ophthalmologists and optometrists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of DED by country, including diagnosed prevalence and prescription drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key therapies for DED through 2029, segmented by brands / generics.
Emerging therapies: Phase III: 7 drugs; coverage of select Phase II drugs.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Dry Eye - Landscape & Forecast - Disease Landscape & Forecast
- COVID-19
- Key Findings
- Key Updates
- Market Outlook
- Key Findings
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Dry Eye Disease?
- What Factors Are Constraining the Market for Dry Eye Disease?
- Market Share and Share of Treated Patients for Dry Eye Disease by Region: 2019 and 2029
- Major-Market Sales and Overall Drug-Treated Patients in Dry Eye Disease: 2019-2029
- Major-Market Brand and Generic Sales in Dry Eye Disease: 2019-2029
- Major-Market Brand and Generic Patient Share in Dry Eye Disease: 2019-2029
- Drug-Class-Specific Trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key Findings
- Treatment Goals
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Dry Eye Disease
- Select Current Drugs Used for Dry Eye Disease
- Market Events Impacting the Use of Key Current Therapies for DED
- Calcineurin Inhibitors (Ophthalmic)
- LFA-1 Antagonists
- Secretagogues
- Artificial Tears
- Corticosteroids (Ophthalmic)
- Other Key Pharmacological Therapies
- Key Nonpharmacological Approaches
- Medical Practice
- Key Findings
- Unmet Need Overview
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
- COVID-19
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.
Emma McFadden, Ph.D., is a director on the CNS/Ophthalmology Disorders team at Clarivate. Her focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored reports in a number of other indications, including multiple sclerosis and epilepsy. Dr. McFadden earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College in Dublin.
Fjoralba Kristo, M.D., M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she completed a postdoctoral fellowship at the University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as a research scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Dr. Kristo holds an M.P.H. degree from Boston University School of Public Health, with a concentration in epidemiology and biostatistics, and a medical degree from the University of Medicine in Bucharest, Romania.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.
Shefali Gulati, M.B.A., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She has authored several CNS/Ophthalmology reports, including U.S. Treatment Algorithms, Unmet need, Special topics. Previously, Ms. Gulati was a knowledge management associate with ZS Associates, where she worked on multiple client projects pertaining to real-world claims data analysis, opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds an M.B.A. in pharmaceutical management from the National Institute of Pharmaceutical Education and Research and a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research.